Trial · NCT01415752
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 12 of 12
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression-free Survival (PFS) for Induction Phase | Induction: Bendamustine + Rituximab (RB; Arms A + C) | 5.5 | 95% Confidence Interval 4.5 to 6.6 | years | |
| Progression-free Survival (PFS) for Induction Phase | Induction: Bendamustine + Rituximab + Bortezomib (RBV; Arms B + D) | 6.4 | 95% Confidence Interval 4.8 to 7.7 | years | |
| Progression-free Survival (PFS) for Maintenance Phase (Step 2) | Maintenance: Rituximab (R; Arms E + F) | 5.9 | 95% Confidence Interval 5.0 to 8.2 | years | |
| Progression-free Survival (PFS) for Maintenance Phase (Step 2) | Maintenance: Lenalidomide + Rituximab (LR; Arms G + H) | 7.2 | 95% Confidence Interval 5.5 to 7.8 | years | |
| Objective Response for Induction Phase (Step 1) | Induction: Bendamustine + Rituximab (RB; Arms A + C) | Objective response | 158 | Participants | |
| Objective Response for Induction Phase (Step 1) | Induction: Bendamustine + Rituximab + Bortezomib (RBV; Arms B + D) | Objective response | 158 | Participants | |
| Objective Response for Induction Phase (Step 1) | Induction: Bendamustine + Rituximab (RB; Arms A + C) | No objective response | 21 | Participants | |
| Objective Response for Induction Phase (Step 1) | Induction: Bendamustine + Rituximab + Bortezomib (RBV; Arms B + D) | No objective response | 21 | Participants | |
| Overall Survival (OS) Rate at 5 Years Since Maintenance (Step 2) | Induction: (A) Bendamustine + Rituximab Then Maintenance: (E) Rituximab | 0.866 | 95% Confidence Interval 0.758 to 0.928 | Proportion of participants | |
| Overall Survival (OS) Rate at 5 Years Since Maintenance (Step 2) | Induction: (B) Bendamustine + Rituximab + Bortezomib Then Maintenance: (F) Rituximab | 0.828 | 95% Confidence Interval 0.711 to 0.901 | Proportion of participants | |
| Overall Survival (OS) Rate at 5 Years Since Maintenance (Step 2) | Induction: (C) Bendamustine + Rituximab Then Maintenance: (G) Lenalidomide + Rituximab | 0.727 | 95% Confidence Interval 0.602 to 0.819 | Proportion of participants | |
| Overall Survival (OS) Rate at 5 Years Since Maintenance (Step 2) | Induction: (D) Bendamustine + Rituximab + Bortezomib Then Maintenance: (H) Lenalidomide + Rituximab | 0.853 | 95% Confidence Interval 0.743 to 0.918 | Proportion of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01415752/results